Source: International Congress 2015 – Pulmonary hypertension: promising small molecules
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Sebastien J. Dumas (Le Plessis-Robinson, France), Sébastien J. Dumas, Frédéric Perros, Gilles Bru-Mercier, Audrey Courboulin, Benoit Ranchoux, Catherine Rücker-Martin, Elodie Gouadon, Matthieu Vocelle, Nicolas Raymond, Peter Dorfmüller, Elie Fadel, Marc Humbert, Sylvia Cohen-Kaminsky. LSC Abstract – Glutamatergic signaling through pulmonary vascular NMDA receptors in pulmonary hypertension. Eur Respir J 2015; 46: Suppl. 59, 4898

Member's Comments

No comment yet.

Related content which might interest you: NMDA receptor activation promotes vascular remodeling and pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 NMDA-type glutamate receptors contribute to the development of pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms Year: 2012 NMDA receptor crosstalk with PDGFR-β and BMPR2 is involved in smooth muscle cell proliferation in pulmonary arterial hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Olfactory receptors in pulmonary arterial hypertension: A novel pathway of vascular remodeling? Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Roundabout (Robo) receptors on pulmonary artery endothelial cells: Implications for pulmonary arterial hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Activation of the Beta-3 adrenoceptor in experimental pulmonary hypertension Source: International Congress 2018 – Experimental research in pulmonary hypertension Year: 2018 Peripheral airway dysfunction persist after endothelin receptor antagonist therapy in patients with idiopathic pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary circulation Year: 2009 Endothelin receptor antagonists in pulmonary arterial hypertension Source: Eur Respir J 2008; 31: 407-415 Year: 2008 Expression of the serotonin 1b receptor in experimental pulmonary hypertension Source: Eur Respir J 2003; 22: 408-412 Year: 2003 Role of NMDA receptors in vascular remodelling associated to pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Role of endothelin B receptor in Th2-induced pulmonary vascular hyperresponsiveness Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 Single centre experience with endothelin receptor blockade in pulmonary hypertension Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004 Dual endothelin receptor blockade: advances in pulmonary disease Source: Annual Congress 2008 - Mastering pulmonary arterial hypertension: defined by evidence - enhanced by experience Year: 2008 Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension? Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018 Year: 2018 Dual endothelin receptor antagonism: setting standards in PAH Source: Eur Respir Rev 2008; 17: 13-18 Year: 2007 TrkB expression is altered in hypoxia-induced pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 606s Year: 2007 Anti-contractile and anti-proliferative responses in human pulmonary arterial smooth muscle cells induced by ACT-333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin receptor agonist Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Endothelial NO and its pathophysiologic regulation Source: Annual Congress 2007 - Role of the endothelium in pulmonary function and disease Year: 2007 Effects of AT1 receptor blockade on pulmonary and systemic manifestations in a COPD/emphysema mouse model Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009